Category IP-Watch Briefs

MSF: Prices On Latest ARV Drugs Under Patent Too High

The price of first- and second-line anti-retrovirals (ARVs) have declined due to increased generic competition, while third-line regimens remain “exorbitantly priced,” according to the latest edition of a publication from Médecins Sans Frontières (MSF).

Medicines Patent Pool Signs New Licence Agreements

The Medicines Patent Pool, Shilpa Medicare, and Gilead Sciences have signed an agreement to increase access to HIV treatment medicines. The agreement will allow Shilpa Medicare to manufacture “five key HIV medicines for sale in 100-112 countries,” and the goal is to cover “a majority of people living with HIV.”

Infojustice.org: UN Consumer Guidelines Could Be Updated For Digital Rights, A2K

Infojustice.org reports: "Over the last three years a global network of consumer activists has been crafting a set of amendments to an influential global instrument, the United Nations Guidelines for Consumer Protection, that could provide a powerful global standard for digital rights and access to knowledge. UNCTAD agreed to their review and set a date – July 11 and 12 – at which to consider proposed amendments."

US Gives Boost To Materials Genome Initiative

The Obama administration and academic and industry partners today announced their commitment to support the Materials Genome Initiative (MGI), a public-private endeavor whose aim is to reduce the time required to develop novel materials that can “fuel advanced manufacturing and bolster the 21st century American economy.”

WIPO Economics Working Paper On Mobility Of Inventors

Central American, Caribbean, and African economies have the most “inventor brain drain” in relation to the number of home country inventors, according to a recent working paper released by the World Intellectual Property Organization. Data for the study included information on inventor nationality and residence available in Patent Cooperation Treaty (PCT) applications.